Clinical trial · Interventional
Yorkshire Enhanced Stop Smoking Study
The Effect of Adding a Personalised Smoking Cessation Intervention to a Lung Cancer Screening Programme
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Lung cancer rates are higher in Yorkshire than the rest of the UK, and this is due to higher rates of smoking. Deaths from lung cancer can be reduced using regular lung scans (screening) and by helping people stop smoking. As well as detecting cancers, scans can also show evidence of damage to lungs (emphysema) and heart arteries (calcification). This study will test whether people can be encouraged to quit smoking by giving them pictures from their own scans showing possible lung and heart damage, along with information about how stopping smoking reduces their risk of cancer and heart attacks.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer, Lung | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Heart Diseases | — | UNRESOLVED | — |
| Respiratory Disease | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Intervention | Other | — | UNRESOLVED |
| Usual Care | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Usual Care
- description
- Smoking Cessation NICE PH48 Guidelines
- interventionNames
- Other: Usual Care
- type
- ACTIVE_COMPARATOR
- label
- Intervention
- description
- Smoking Cessation NICE PH48 Guidelines plus personalised feedback from Lung Scan
- interventionNames
- Other: Intervention
Primary outcomes (1)
- measure
- 7-day point prevalent CO validated smoking cessation.
- timeFrame
- Three months after lung screening
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 55 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Residing in the newly merged Leeds South \& East, Leeds West or Leeds North CCG * Registered as a current or ex-smoker in a General Practice participating in YLST * Have attended for a 'Lung Health Check' and agreed to see the SCP as part of YLST * Smoked within the last month or have exhaled CO reading of 6ppm or above. * Have capacity to provide informed consent.
References
Publications (4)
- DERIVEDMurray RL, Baldwin D, Brain K, Britton J, Chalitsios CV, Crosbie PA, Lewis S, McCutchan G, Steve P, Quaife S, Thorley R, Wu Q, Ashurst A, Beeken RJ, Copeland H, Gabe R, Hancock N, Marshall CS, Neal RD, Porter LR, Rogerson S, Quinn-Scoggins HD, Simmonds I, Sloss A, Callister MEJ. Randomised trial of delivering co-located, personalised stop-smoking support within lung cancer screening: the YESS study. Thorax. 2026 Mar 13:thorax-2025-224217. doi: 10.1136/thorax-2025-224217. Online ahead of print. PMID 41825863
- DERIVEDMcInnerney D, Simmonds I, Hancock N, Rogerson S, Lindop J, Gabe R, Vulkan D, Marshall C, Crosbie PAJ, Callister MEJ, Quaife SL. Yorkshire Lung Screening Trial (YLST) pathway navigation study: a protocol for a nested randomised controlled trial to evaluate the effect of a pathway navigation intervention on lung cancer screening uptake. BMJ Open. 2024 Jul 9;14(7):e084577. doi: 10.1136/bmjopen-2024-084577. PMID 38986555
- DERIVEDMurray RL, Brain K, Britton J, Quinn-Scoggins HD, Lewis S, McCutchan GM, Quaife SL, Wu Q, Ashurst A, Baldwin D, Crosbie PAJ, Neal RD, Parrott S, Rogerson S, Thorley R, Callister ME. Yorkshire Enhanced Stop Smoking (YESS) study: a protocol for a randomised controlled trial to evaluate the effect of adding a personalised smoking cessation intervention to a lung cancer screening programme. BMJ Open. 2020 Sep 10;10(9):e037086. doi: 10.1136/bmjopen-2020-037086. PMID 32912948
- DERIVEDCrosbie PA, Gabe R, Simmonds I, Kennedy M, Rogerson S, Ahmed N, Baldwin DR, Booton R, Cochrane A, Darby M, Franks K, Hinde S, Janes SM, Macleod U, Messenger M, Moller H, Murray RL, Neal RD, Quaife SL, Sculpher M, Tharmanathan P, Torgerson D, Callister ME. Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care in a targeted population at risk. BMJ Open. 2020 Sep 10;10(9):e037075. doi: 10.1136/bmjopen-2020-037075. PMID 32912947